Creatine and GLP-1 Microdosing: The Supplement With the Best Case for Protecting Lean Mass While the Scale Falls

Of every supplement sold to people losing weight, creatine monohydrate is the one with the deepest evidence base, the lowest cost, and the most direct answer to the problem GLP-1 users actually have. That problem is lean mass. In the STEP 1 DEXA substudy, 39 percent of the weight lost on semaglutide came from lean tissue rather than fat.

Creatine does not burn fat and it does not suppress appetite. What creatine does is refill the phosphocreatine system that powers the first seconds of every hard set, let a person train harder for longer, pull water into the muscle cell, and, across more than 500 published trials, add lean mass and strength on top of whatever resistance training alone delivers. Those are the mechanisms that matter when total energy intake has fallen by a third and the body is deciding what to keep.

This article covers what creatine is and where the body gets it, how much lean mass the GLP-1 trials lost, what the meta-analyses in older adults show, why a loading phase is the wrong choice on a GLP-1, why creatine will change a creatinine result and an estimated GFR without changing kidney function, which groups have the most to gain, and what is still unknown. No trial has yet combined creatine with semaglutide or tirzepatide, and the article is clear about where the two literatures meet and where they merely sit side by side.

What is creatine and where does the body get it?

A fuel buffer the liver makes and meat supplies

Creatine is a small nitrogen containing compound that the liver, kidneys, and pancreas make from three amino acids, and that muscle stores as phosphocreatine to regenerate ATP during the first 5 to 10 seconds of intense effort. The body makes roughly 1 gram a day and an omnivorous diet supplies another 1 to 2 grams, almost all of it from meat and fish. About 95 percent of the body's creatine is held in skeletal muscle, at roughly 120 to 125 millimoles per kilogram of dry muscle in a typical omnivore, and it turns over at about 2 percent a day as it breaks down to creatinine and leaves in the urine.

Muscle stores have a ceiling of around 160 millimoles per kilogram of dry muscle, and the gap between a person's baseline and that ceiling is what supplementation fills. Harris and colleagues established this in 1992 by taking muscle biopsies before and after 20 grams a day of creatine monohydrate: stores rose by about 20 percent in five days, with the largest gains in the people who started lowest. Vegetarians start lowest of all. Burke and colleagues measured muscle creatine at 117 millimoles per kilogram in vegetarians against 130 in omnivores, and the vegetarians gained more lean mass and strength when supplemented.

The dietary side matters on a GLP-1 because meat intake usually falls. Appetite for dense protein foods drops, portion sizes shrink, and the taste changes described in the taste changes article on this site often push people away from red meat in particular. Someone who went from a 200 gram steak most evenings to a few bites of chicken has cut their dietary creatine from roughly 1 gram a day toward zero, and their muscle stores drift down toward the vegetarian range over weeks. That drift is invisible on any standard blood test and it is one of the quieter ways lean mass slips on these drugs.

How much lean mass is lost on a GLP-1?

A quarter to two fifths of the weight, by DEXA

Between 25 and 40 percent of the weight lost on a GLP-1 receptor agonist at labelled doses is lean mass rather than fat, according to the DEXA substudies of the two pivotal trials. In the STEP 1 substudy of 140 participants, semaglutide 2.4 mg reduced fat mass by 8.4 kilograms and lean mass by 5.3 kilograms over 68 weeks, so lean tissue made up 39 percent of the total. In the SURMOUNT-1 substudy of 160 participants, tirzepatide reduced fat mass by 33.9 percent and lean mass by 10.9 percent, which works out to roughly a quarter of the weight lost coming from lean tissue.

Those proportions are not unusual for weight loss in general. Chaston and colleagues reviewed diet induced weight loss studies in 2007 and found that about a quarter of the weight lost was fat free mass, which is the same range as the tirzepatide result. The STEP 1 figure sits at the high end, and the trial investigators noted that the ratio of lean to fat mass actually improved because fat fell faster than lean. The concern is not that GLP-1s cause unusual muscle loss; it is that any large, fast loss of weight takes muscle with it, and that the people taking these drugs are often over 50, often sedentary, and often eating well under a gram of protein per kilogram a day during the first months.

The muscle retention article on this site covers protein targets and resistance training, which remain the two most important levers. Creatine is the third lever, and it is a supporting one: it makes the training more productive and the muscle cell better hydrated and better fuelled. The lean mass question also bears on the choice of dose. A low dose that produces slower weight loss gives the body more time to adapt, and the muscle preservation article on this site sets out why the rate of loss matters as much as the total.

What does creatine do for lean mass and strength?

The meta-analyses in the age group most GLP-1 users belong to

Creatine combined with resistance training adds roughly 1 to 1.5 kilograms more lean mass than resistance training alone, and the effect is clearest in adults over 50. Chilibeck and colleagues pooled 22 randomised trials with 721 participants aged 50 and over in 2017 and found that creatine added 1.37 kilograms more lean tissue mass than placebo, alongside greater gains in chest press and leg press strength. Forbes and colleagues then pooled 19 trials with 609 older participants in 2019 and found creatine produced a 0.55 kilogram greater reduction in fat mass and a 1.19 point greater reduction in body fat percentage, even though creatine itself has no direct effect on fat.

The mechanism runs through training quality. A muscle with fuller phosphocreatine stores regenerates ATP faster between repetitions, so the person completes more work per session before fatigue, and the extra work is what drives adaptation. Creatine also draws water into the muscle cell, and cell swelling is itself a signal that favours protein synthesis and limits breakdown. Several studies have found lower markers of muscle protein breakdown and reduced inflammatory markers after hard exercise in supplemented people. In short, creatine amplifies the response to lifting; it does not replace it. Trials of creatine without exercise show little change in lean mass beyond the initial water gain.

The energy deficit is the setting where this matters most. Muscle protein synthesis falls when energy intake falls, and a person on a GLP-1 eating 1,200 to 1,500 calories a day is training in exactly that state. No trial has tested creatine specifically in GLP-1 users, and the closest evidence comes from studies of creatine during energy restriction in athletes and older adults, which have generally found that supplemented groups kept more lean mass and strength than placebo groups making the same cut. The direction is consistent and the magnitudes are modest, which is the honest description of most of what creatine does.

How much creatine, and why not load on a GLP-1?

Same destination, slower road, fewer stomach complaints

The effective dose is 3 to 5 grams of creatine monohydrate a day, taken every day including rest days, and a loading phase is optional. The ISSN position stand describes two routes to saturation: 20 grams a day split into four doses for five to seven days, or 3 to 5 grams a day from the start. Hultman and colleagues showed in 1996 that both routes reach the same muscle creatine content; the loading route gets there in about a week and the steady route in about four weeks. After saturation, 3 to 5 grams a day replaces the roughly 2 percent lost daily and holds the level indefinitely.

On a GLP-1 the loading phase is the wrong choice for a specific reason: gastrointestinal tolerance. Creatine doses of 10 grams at a time cause diarrhoea and stomach upset in a substantial fraction of people, and Ostojic and Ahmetovic found in 2008 that gastrointestinal complaints scaled with dose size. A GLP-1 has already slowed gastric emptying, and the acid reflux and constipation articles on this site describe how much of the early side effect burden comes from the stomach. Adding 5 grams four times a day to that stomach for a week is a good way to blame creatine for nausea that would have resolved on its own with a smaller dose. The steady route is slower by three weeks and costs nothing in outcome.

Absorption is not a concern despite the slowed emptying. Creatine monohydrate is absorbed almost completely in the small intestine, and delaying gastric emptying delays the peak in blood creatine without reducing the total taken up. Because creatine works by accumulating in muscle over weeks, the timing of any single dose has little bearing on the result. Taking it with a meal that contains carbohydrate or protein modestly increases uptake, and dissolving the powder in warm liquid helps it dissolve fully, which is the single most effective step for reducing stomach complaints. Creatine monohydrate is the form with the evidence; the more expensive variants have not shown any advantage in head to head trials.

Why does creatine change a creatinine test and an estimated GFR?

The input to the equation moves, the kidneys do not

Creatine supplementation raises serum creatinine by roughly 5 to 15 percent because creatine breaks down to creatinine at a fixed rate, and more creatine in the body means more creatinine in the blood. That rise has nothing to do with kidney function, but estimated GFR is calculated from serum creatinine, so a higher creatinine automatically produces a lower estimate. For a 45 year old woman whose creatinine rises from 0.82 to 0.93 milligrams per decilitre, the CKD-EPI estimate falls from about 96 to about 83, which is enough to trigger a flag on a lab report and a worried phone call.

This matters on a GLP-1 because kidney function is monitored more often than usual. Prescribers check creatinine and estimated GFR at baseline and during titration, and the kidney function article on this site explains why: the early weeks carry a real risk of dehydration from nausea, vomiting, and reduced fluid intake, and acute kidney injury has been reported in that setting. A creatinine that rises for two different reasons, one harmless and one not, is genuinely hard to interpret, and the way to separate them is to tell the clinician about the creatine and, if needed, measure cystatin C. Cystatin C is a different marker of filtration that creatine does not affect, and an estimated GFR based on it will read normal when the creatinine based one does not.

The long term safety data are reassuring for people with normal kidneys. Poortmans and Francaux followed athletes taking creatine for up to five years and found no change in measured kidney function, and the ISSN position stand and subsequent reviews have found no evidence of kidney harm in healthy people at recommended doses across hundreds of trials. The picture is different for people with existing kidney disease, where creatine has not been well studied and where a rising creatinine cannot be assumed to be benign. Anyone with a reduced estimated GFR before starting should raise creatine with the nephrologist rather than the supplement shop.

Who has the most to gain from creatine on a GLP-1?

Women, people over 50, and anyone who has stopped eating meat

Women, adults over 50, and people eating little meat or fish have the strongest case for creatine, and all three groups are heavily represented among GLP-1 users. Women carry 70 to 80 percent less creatine in their stores than men, according to the 2021 review by Smith-Ryan and colleagues, partly because of lower muscle mass and partly because of lower dietary intake, and the same review argued that the relative benefit may therefore be larger. The women over 40 article on this site describes how the loss of oestrogen accelerates muscle loss through the menopause transition, and creatine studies in postmenopausal women have found preserved strength and, with resistance training, preserved bone density at the hip.

In older adults the meta-analyses already described give the clearest picture, and the bone density article on this site explains why the combination of muscle loss and bone loss during rapid weight loss is the pattern most worth interrupting. Creatine has a cognitive literature as well, with a 2023 meta-analysis by Prokopidis and colleagues finding improved memory performance in supplemented adults, largest in those aged 66 to 76. The fatigue article on this site notes that low energy on a GLP-1 is often a sign of under fuelling, and creatine is one of the few supplements with any evidence of reducing mental fatigue under load.

The dietary group is the one most easily overlooked. Anyone who has moved away from meat and fish, whether by long standing choice or because a GLP-1 has changed what appeals, is running on the roughly 1 gram a day the body makes and nothing more. Burke and colleagues found that vegetarians started with lower muscle creatine and gained more lean mass and strength from supplementation than omnivores did. A person whose plate now holds mostly yoghurt, eggs, and protein shakes is in the same position, and the effect of 3 to 5 grams a day is likely to be at the larger end of the range for them.

What does a sensible creatine approach look like alongside a GLP-1 microdose?

Six points, none of which are a prescription

Everything below is context for a conversation with the prescriber rather than an instruction. Creatine is a supplement with a strong safety record in healthy adults, and it is still worth declaring to the clinician managing the GLP-1, because it changes a lab value they are watching.

What is genuinely unresolved here?

Three gaps worth naming

No published trial has combined creatine with semaglutide, tirzepatide, or any other GLP-1 receptor agonist at any dose. The lean mass data come from the GLP-1 trials, the creatine data come from resistance training trials in people not taking a GLP-1, and the argument that the second addresses the first is an inference. It is a well founded inference, because the mechanism of creatine does not depend on how the energy deficit was created, but it has not been tested, and the size of the benefit in someone eating 1,300 calories a day with a suppressed appetite for protein is unknown.

The hair loss question is closed on the evidence but open in the public mind. The 2009 van der Merwe study found a 56 percent rise in dihydrotestosterone during a loading phase in 20 rugby players, did not measure hair, and has not been replicated. Antonio and colleagues reviewed 12 subsequent studies in 2021 and found no consistent effect on testosterone, free testosterone, or DHT and no evidence of hair loss. Because hair shedding from rapid weight loss is common on a GLP-1, as the hair loss article on this site describes, people who start creatine at the same time may attribute telogen effluvium to the supplement. The two are unrelated on the available data.

The lean mass figures from DEXA overstate the muscle at stake. Lean mass on DEXA includes water, organ tissue, connective tissue, and bone mineral, and some of the lean loss on a GLP-1 is water and organ mass that shrinks appropriately as body size falls. The share that is skeletal muscle is smaller than 39 percent, and how much of that muscle is functionally meaningful, as opposed to the extra tissue carried to move a heavier body, is debated. Creatine's water gain will also register as lean mass on DEXA, which flatters the number without necessarily adding contractile tissue. Grip strength, leg press, and the ability to rise from a chair without hands are more honest measures of whether the muscle that matters is being kept.

Frequently Asked Questions